welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
rareCurate
view full news & meetings section

FDA paves way for clinical trials of Sarepta’s Duchenne MD therapy SRP-5051


The U.S. Food and Drug Administration has taken a step that will allow Sarepta Therapeutics to start clinical trials of its Duchenne muscular dystrophy therapy SRP-5051.

That move was accepting the company’s Investigational New Drug application for SRP-5051. The therapy, known as a peptide phosphorodiamidate morpholino oligomer, is designed to treat those whose Duchenne MD stems from the exon 51 genetic mutation. They constitute the largest group of DMD patients — about 13 percent.

Genes are made up of dozens of components known as exons. A missing exon can lead to a gene mutation that generates a faulty protein, causing a disease.

 

FDA Paves Way For Clinical Trials Of Sarepta’s Duchenne MD Therapy SRP-5051
Source: https://musculardystrophynews.com/2017/11/13/fda-paves-way-for-clinical-trials-of-sareptas-duchenne-md-therapy-srp-5051/

rareRelated